Drugs / GR1014-CG 2.4%
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07192588 | Jul 2024 → Sep 2026 overdue | radiodermatitis | Graegis Pharmaceuticals Ltd | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GR1014-CG 2.4% | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07192588 ↗ |